Surveys with a longer follow-up are recommended in order to ascertain for how long a single administration of triclabendazole can sustain low prevalence and intensity of infection in endemic areas. Such a study would allow the most appropriate interval of re-treatment Navitoclax mw to be determined. Following the successful implementation of the pilot intervention, the health authorities of Bolivia decided to implement distribution of triclabendazole on a large scale. Acknowledgments The authors would like to express their gratitude to the National, Departmental, Provincial, Municipal and Traditional Authorities of Bolivia that saw the worth of the activities described in this article. Special thanks are due to the manager and staff of the Health Network n.9 in the municipality of Tiwanaku and to all the members of the community of Huacullani.
The authors would like to express their gratitude to Drs. Denis Daumerie and Lester Chitsulo for their contributions to the activities mentioned in this article, and to Mr. Patrick Tissot for his help in the finalization of the manuscript. Members of the SEDES �C La Paz Members of SEDES �C La Paz that contributed to the activities described in this article include Ren�� Barrientos, Rosmery Carvallo, Karla Espinoza Sanabria and Luz Mery Huanca. Funding Statement The tablets of triclabendazole (Egaten?) used in the pilot intervention were provided by Novartis Pharma AG. Novartis Pharma AG had no role in study design, data collection and analysis, and decision to publish. The two co-authors from Novartis revised the draft manuscript.
The WHO financially supported field activities and was involved in study design, data collection and analysis, decision to publish, and preparation of the manuscript. Participation of the members of the Parasitology Department of Valencia was supported by Projects SAF 2006-09278 and SAF 2010-20805 of the Spanish Ministry of Science and Technology, Madrid, and by the Red de Investigaci��n de Centros de Enfermedades Tropicales �C RICET (grant no. ISCIII-RETIC RD06/0021/0017 of the Programa de Redes Tem��ticas de Investigaci��n Cooperativa RETICS/FEDER) of the Fondo de Investigaci��n Sanitaria (FIS), Ministry of Health, Madrid. The mentioned funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Aberrant signalling by phosphatidylinositol-3-kinase (PI3K) is a prominent feature of pancreatic cancers, due to the high prevalence of abnormalities that regulate this pathway, including K-ras mutations that occur in approximately 90% of cases, increased expression of receptor tyrosine kinases like EGFR, and loss of PTEN (Korc, 1998; Ruggeri et al, 1998; Bardeesy Dacomitinib and DePinho, 2002; Agbunag and Bar-Sagi, 2004; Asano et al, 2004; Chadha et al, 2006).